While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...

Ambrosia Biosciences is aiming to move the market beyond peptide-based obesity treatments and initiate a trial for its oral ...

Mantis takes disparate sources of data to make synthetic datasets that can be used to build so-called "digital twins" of the ...

Half a year after being spurned by the FDA and following deep layoffs, IO Biotech has decided to close its doors for good.

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force behind this resurgence.

The six companies that have priced initial public offerings so far banked a median of $287.5 million, a figure far surpassing ...

Mantis Biotechnology Corp, a San Francisco-based startup, is building simulated human bodies to generate the synthetic ...

U.S. venture capital firms are no longer waiting for Chinese biotech assets to surface before investing in them — they’re ...

PSC Biotech partners with Blue Ocean Robotics to distribute the UVD Robot Pharma delivering autonomous UV C disinfection for GMP cleanroom environments. Purpose built for GMP cleanroom environments, ...

Discover the Latest in Research Peptides at Biotech Labz Supply Sebastopol, United States - January 3, 2026 / Biotech ...

Shares of IO Biotech, Inc. IOBT are plummeting Tuesday after the company announced it filed for Chapter 7 bankruptcy and will ...

After several years of IPO drought in the biotech industry, the public market is picking up again. Will the trend keep going ...